Vir Biotechnology (VIR) reported positive data from updated Phase 2 results in chronic hepatitis delta, showing that the combination of its investigational therapies tobevibart and elebsiran was well tolerated.

The company said Monday in a statement that 88% of patients had no detectable hepatitis D virus in their blood at 96 weeks.

Vir said it will present new Phase 1 data for VIR-5500, an experimental prostate-cancer therapy, at the American Society of Clinical Oncology's Genitourinary Cancers Symposium in February.

The company ended 2025 with about $781 million in cash and investments, extending its cash runway into Q4 2027.

Vir said it expects multiple clinical milestones in 2026, including initial topline data from its Phase 3 chronic hepatitis delta program.

Vir shares rose 1.6% in recent Tuesday trading.

Price: 6.02, Change: +0.09, Percent Change: +1.60